Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.
about
Microglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In VivoScreening of a specific peptide binding to VPAC1 receptor from a phage display peptide libraryVIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines.Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomasPituitary adenylate cyclase activating peptide deficient mice exhibit impaired thymic and extrathymic regulatory T cell proliferation during EAETargeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.Single nucleotide polymorphisms in the 3'UTR of VPAC-1 cooperate in modulating gene expression and impact differently on the interaction with miR525-5p.Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges.Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice.Tuning inflammation with anti-inflammatory neuropeptides.Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disordersVIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repairPACAP and VIP Inhibit the Invasiveness of Glioblastoma Cells Exposed to Hypoxia through the Regulation of HIFs and EGFR ExpressionRegulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans.Homeostatic and therapeutic roles of VIP in smooth muscle function: myo-neuroimmune interactions.TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells.Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.Role of neuropeptides in skin inflammation and its involvement in diabetic wound healing.Cyclic AMP: a selective modulator of NF-κB action.Interleukin-12: clinical usage and molecular markers of cancer susceptibility.Vasoactive intestinal peptide enhances TNF-α-induced IL-6 and IL-8 synthesis in human proximal renal tubular epithelial cells by NF-κB-dependent mechanism.Breaking human cytomegalovirus major immediate-early gene silence by vasoactive intestinal peptide stimulation of the protein kinase A-CREB-TORC2 signaling cascade in human pluripotent embryonal NTera2 cells.VIP inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in monocytes.A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiationInhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
P2860
Q26798185-3CB314B8-F683-43C3-BBF6-CFB0CF5DD878Q28485298-50821F1D-4500-44A3-A6D7-CC1F4E7B4FDDQ33838543-DBFD534B-8473-483F-B6B3-C1A0BCE1C28DQ34246553-7A4ED90E-5FD5-4C8F-9C34-B5E1FFBA9E35Q34684150-A7404DA7-0544-4CC6-97A7-15F9F8263A73Q35295564-5409FE5F-2D8D-4B26-82BD-BBB561C0B06BQ35414146-BF1C58DD-68EE-409A-93C0-849F7DBF8574Q35684429-9ACA61E1-2E15-42FB-96B3-075AC137E862Q36393098-45017749-F74A-4E98-8B41-DFCC725CABCBQ36764912-CA00519F-279A-4BA4-B1F8-13BA0201FB70Q36830470-21249291-D3C3-46CD-BE47-7DB8385FF4F4Q36929423-FE1AE38A-18FC-4C44-A242-A065D27486F0Q36948641-224F87C5-4E6B-41AF-A61D-19F99AD8EA9AQ37374938-85C69324-F824-46E0-A887-5675BA1A21A0Q37391804-7F93DA74-CF5F-4356-BFE0-4D695D74DB99Q37408129-87CF30E7-7882-4583-8CE0-A8E5323ABF33Q37552024-9163E6F5-E08E-4F1D-9016-E4EF29F42432Q37782353-E56F8317-3BE7-48F8-965C-F8043153F639Q37899788-BB7DF62A-96F8-4381-A979-E2D87F51F528Q38003641-71ACB351-ABD6-492D-9BBD-3F1EE2DA5ADEQ39420647-290C25B1-B887-45D1-980C-85891032D81BQ39860663-E4054495-AB6B-4593-88BB-DB402F88896FQ40089306-207F0867-E859-4714-A22F-54EE6658B44AQ42734546-3146117C-E272-4BEA-8258-B6C6AACE4C02Q43949268-F6BFF9C8-0808-4DF7-AF83-B6E0AD15BF79Q44060393-A488D189-F01D-4788-8272-3C6FD2B65B8A
P2860
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Vasoactive intestinal peptide ...... tor kappaB and Ets activation.
@en
type
label
Vasoactive intestinal peptide ...... tor kappaB and Ets activation.
@en
prefLabel
Vasoactive intestinal peptide ...... tor kappaB and Ets activation.
@en
P2860
P356
P1476
Vasoactive intestinal peptide ...... tor kappaB and Ets activation.
@en
P2093
P2860
P304
31930-31940
P356
10.1074/JBC.274.45.31930
P407
P577
1999-11-01T00:00:00Z